相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer
Mitsukuni Suenaga et al.
EUROPEAN JOURNAL OF CANCER (2017)
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
M. Suenaga et al.
ANNALS OF ONCOLOGY (2017)
Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current methods of the analysis of immunosuppressive agents in clinical materials: A review
Adriana Mika et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
TAS-102, a novel antitumor agent: A review of the mechanism of action
Heinz-Josef Lenz et al.
CANCER TREATMENT REVIEWS (2015)
Selection of Patients for Anti-Epidermal Growth Factor Receptor Treatment in Colorectal Cancer: The Potential Pitfalls of Retrospective Analyses of RAS Mutations
Sylwia Debska-Szmich et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks
Kazuaki Matsuoka et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetics, diagnosis and management of colorectal cancer
Marina De Rosa et al.
ONCOLOGY REPORTS (2015)
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
Nozomu Tanaka et al.
ONCOLOGY REPORTS (2014)
Biologic therapies in the metastatic colorectal cancer treatment continuum - Applying current evidence to clinical practice
Marc Peeters et al.
CANCER TREATMENT REVIEWS (2012)
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
Claus-Henning Koehne et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
MALDI imaging mass spectrometry: bridging biology and chemistry in drug development
Stephen Castellino et al.
BIOANALYSIS (2011)
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
M. Wasif Saif et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
